Eif2B4 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
eIF2B4 is the delta subunit of the eukaryotic translation initiation factor 2B complex. The eIF2B heterodecamer consists of two copies each of five subunits (alpha, beta, gamma, delta, epsilon), forming a symmetrical complex. The delta subunit plays a structural role in maintaining complex integrity and contributes to the regulatory functions of eIF2B[@structure2015].
...
eIF2B4 Protein
Introduction
Eif2B4 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
eIF2B4 is the delta subunit of the eukaryotic translation initiation factor 2B complex. The eIF2B heterodecamer consists of two copies each of five subunits (alpha, beta, gamma, delta, epsilon), forming a symmetrical complex. The delta subunit plays a structural role in maintaining complex integrity and contributes to the regulatory functions of eIF2B[@structure2015].
The eIF2B complex serves as the guanine nucleotide exchange factor (GEF) for eIF2, catalyzing the exchange of GDP for GTP to regenerate active eIF2-GTP. This reaction is essential for translation initiation as the eIF2-GTP-Met-tRNAi ternary complex is required for start codon recognition at the ribosome. eIF2B is centrally involved in the integrated stress response (ISR), where phosphorylation of eIF2alpha inhibits eIF2B activity[@eifb2018].
Normal Function
In the normal nervous system, eIF2B4 plays a critical role in regulating protein synthesis in [neurons](/entities/neurons) and glial cells. The eIF2B complex is a central regulator of the ISR, allowing cells to modulate translation in response to various stresses. Under stress conditions, eIF2B inhibition reduces global translation while selectively promoting expression of stress-response genes[@vwm2019].
In oligodendrocytes, eIF2B function is essential for myelin production and maintenance. The stress-responsive regulation through eIF2B helps glial cells cope with the high metabolic demands of myelination and respond to cellular stress.
Role in Disease
Vanishing White Matter Disease (VWM)
Mutations in EIF2B4 are a well-established cause of vanishing white matter disease (VWM), accounting for a significant portion of cases. VWM is characterized by progressive cerebellar ataxia, spasticity, and cognitive decline, with characteristic MRI findings of diffuse white matter rarefaction. Pathogenic variants in EIF2B4 result in partial loss of eIF2B function, impairing the integrated stress response in glial cells[@eifb2010].
The pathophysiology involves impaired stress response in oligodendrocytes, which compromises their ability to handle various cellular stresses, ultimately resulting in myelin vacuolization and loss.
Therapeutic Targeting
Therapeutic approaches for VWM focus on enhancing eIF2B activity:
ISRIB (Integrated Stress Response Inhibitor): A small molecule that stabilizes eIF2B and restores function despite eIF2alpha phosphorylation. Shows promise in preclinical models[@isrib2018].
Pharmacological approaches: Additional compounds that can enhance eIF2B activity are under development.
Gene therapy: Viral delivery of wild-type EIF2B4 to restore normal function.
Key Publications
[Structure of the eIF2B decameric GEF complex (2015)](https://doi.org/10.1038/nature14888)
[eIF2B and mechanism of translational control (2018)](https://doi.org/10.1016/j.tibs.2018.04.004)
[VWM disease: pathophysiology and therapy (2019)](https://doi.org/10.1016/j.neuropharm.2019.107783)
[EIF2B4 mutations in VWM: clinical spectrum (2010)](https://pubmed.ncbi.nlm.nih.gov/20401335/)
[Therapeutic targeting of eIF2B in leukodystrophy (2021)](https://doi.org/10.1016/j.pharmthera.2021.107856)
Background
The study of Eif2B4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.